Comprehensive Analysis to Identify DLEU2L/TAOK1 Axis As a Prognostic Biomarker in Hepatocellular Carcinoma

Overview

Journal Mol Ther Nucleic Acids

Publisher Cell Press

Date 2021 Feb 12

PMID 33575116

Citations 26

Authors

Yi Shi

Dan-Dan Zhang

Ji-Bin Liu

Xiao-Li Yang

Rui Xin

Cheng-You Jia

Hui-Min Wang

Gai-Xia Lu

Pei-Yao Wang

Yu Liu

Zi-Jin Li

Jing Deng

Qin-Lu Lin

Liang Ma

Shan-Shan Feng

Xiao-Qi Chen

Xiang-Min Zheng

Ya-Fu Zhou

Yong-Jun Hu

Hua-Qun Yin

Lin-Lin Tian

Li-Peng Gu

Zhong-Wei Lv

Fei Yu

Wen Li

Yu-Shui Ma

Fu Da

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors that are harmful to human health. Increasing evidence has underscored the critical role of the competitive endogenous RNA (ceRNA) regulatory networks among various human cancers. However, the complexity and behavior characteristics of the ceRNA network in HCC were still unclear. In this study, we aimed to clarify a phosphatase and tensin homolog (PTEN)-related ceRNA regulatory network and identify potential prognostic markers associated with HCC. The expression profiles of three RNAs (long non-coding RNAs [lncRNAs], microRNAs [miRNAs], and mRNAs) were extracted from The Cancer Genome Atlas (TCGA) database. The DLEU2L-hsa-miR-100-5p/ hsa-miR-99a-5p-TAOK1 ceRNA network related to the prognosis of HCC was obtained by performing bioinformatics analysis. Importantly, we identified the DLEU2L/TAOK1 axis in the ceRNA by using correlation analysis, and it appeared to become a clinical prognostic model by Cox regression analysis. Furthermore, methylation analyses suggested that the abnormal upregulation of the DLEU2L/TAOK1 axis likely resulted from hypomethylation, and immune infiltration analysis showed that the DLEU2L/TAOK1 axis may have an impact on the changes in the tumor immune microenvironment and the development of HCC. In summary, the current study constructing a ceRNA-based DLEU2L/TAOK1 axis might be a novel important prognostic factor associated with the diagnosis and prognosis of HCC.

Citing Articles

miR‑100: A key tumor suppressor regulatory factor in human malignant tumors (Review).

Zhang L, Zhang J, Zhang X, Liu S, Qi C, Gao S Int J Mol Med. 2025; 55(4).

PMID: 40017111 PMC: 11875724. DOI: 10.3892/ijmm.2025.5508.

Deferasirox Targets TAOK1 to Induce p53-Mediated Apoptosis in Esophageal Squamous Cell Carcinoma.

Li B, Liu S, Zhou X, Hou D, Jia H, Tang R Int J Mol Sci. 2025; 26(4).

PMID: 40003990 PMC: 11855378. DOI: 10.3390/ijms26041524.

Identification of SLC31A1 as a prognostic biomarker and a target for therapeutics in breast cancer.

Fu H, Dong S, Li K Sci Rep. 2024; 14(1):25120.

PMID: 39448672 PMC: 11502855. DOI: 10.1038/s41598-024-76162-x.

TAOK1-mediated regulation of the YAP/TEAD pathway as a potential therapeutic target in heart failure.

Zhou J, Wu C, Zhao M PLoS One. 2024; 19(8):e0308619.

PMID: 39121041 PMC: 11315341. DOI: 10.1371/journal.pone.0308619.

CDKL3 is a promising biomarker for diagnosis and prognosis prediction in patients with hepatocellular carcinoma.

Wu Q, Lu M, Ouyang H, Zhou T, Lei J, Wang P Exp Biol Med (Maywood). 2024; 249:10106.

PMID: 38993199 PMC: 11237920. DOI: 10.3389/ebm.2024.10106.

References

Zhou R, Sun H, Zheng S, Zhang J, Zeng D, Wu J . A stroma-related lncRNA panel for predicting recurrence and adjuvant chemotherapy benefit in patients with early-stage colon cancer. J Cell Mol Med. 2020; 24(5):3229-3241. PMC: 7077592. DOI: 10.1111/jcmm.14999. View

Chen Z, Zheng Z, Feng L, Huo Z, Huang L, Fu M . Overexpression of miR-382 Sensitizes Hepatocellular Carcinoma Cells to γδ T Cells by Inhibiting the Expression of c-FLIP. Mol Ther Oncolytics. 2020; 18:467-475. PMC: 7479278. DOI: 10.1016/j.omto.2020.07.012. View

Mu M, Niu W, Zhang X, Hu S, Niu C . LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway. Oncogene. 2020; 39(45):6879-6892. PMC: 7644463. DOI: 10.1038/s41388-020-01466-x. View

Wu W, Jing D, Meng Z, Hu B, Zhong B, Deng X . FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity. Theranostics. 2020; 10(6):2859-2871. PMC: 7052884. DOI: 10.7150/thno.41279. View

Yu F, Chen B, Dong P, Zheng J . HOTAIR Epigenetically Modulates PTEN Expression via MicroRNA-29b: A Novel Mechanism in Regulation of Liver Fibrosis. Mol Ther. 2020; 28(12):2703. PMC: 7704723. DOI: 10.1016/j.ymthe.2020.10.021. View

Zhen L, Zhao Q, Lu J, Deng S, Xu Z, Zhang L . miR-301a-PTEN-AKT Signaling Induces Cardiomyocyte Proliferation and Promotes Cardiac Repair Post-MI. Mol Ther Nucleic Acids. 2020; 22:251-262. PMC: 7515978. DOI: 10.1016/j.omtn.2020.08.033. View

Hou J, Zhang H, Liu J, Zhao Z, Wang J, Lu Z . YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma. Mol Cancer. 2019; 18(1):163. PMC: 6859620. DOI: 10.1186/s12943-019-1082-3. View

Liu J, Ding J, Qu B, Liu J, Song X, Suo Q . CircPSMC3 alleviates the symptoms of PCOS by sponging miR-296-3p and regulating PTEN expression. J Cell Mol Med. 2020; 24(18):11001-11011. PMC: 7521274. DOI: 10.1111/jcmm.15747. View

Hu J, Dong Y, Ding L, Dong Y, Wu Z, Wang W . Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment. Signal Transduct Target Ther. 2019; 4:28. PMC: 6799825. DOI: 10.1038/s41392-019-0062-9. View

10.

Cao L, Yang X, Chen Y, Zhang D, Jiang X, Xue P . Exosomal miR-21 regulates the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth. Mol Cancer. 2019; 18(1):148. PMC: 6815431. DOI: 10.1186/s12943-019-1075-2. View

11.

Chen Z, Hu H . Identification of prognosis biomarkers of prostatic cancer in a cohort of 498 patients from TCGA. Curr Probl Cancer. 2019; 43(6):100503. DOI: 10.1016/j.currproblcancer.2019.100503. View

12.

Kim Y, Jo M, Schmidt J, Luo X, Prakash T, Zhou T . Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models. Mol Ther. 2019; 27(9):1547-1557. PMC: 6731179. DOI: 10.1016/j.ymthe.2019.06.009. View

13.

Mi X, Xu R, Hong S, Xu T, Zhang W, Liu M . M2 Macrophage-Derived Exosomal lncRNA AFAP1-AS1 and MicroRNA-26a Affect Cell Migration and Metastasis in Esophageal Cancer. Mol Ther Nucleic Acids. 2020; 22:779-790. PMC: 7595846. DOI: 10.1016/j.omtn.2020.09.035. View

14.

Sun G, Li Z, He Z, Wang W, Wang S, Zhang X . Circular RNA MCTP2 inhibits cisplatin resistance in gastric cancer by miR-99a-5p-mediated induction of MTMR3 expression. J Exp Clin Cancer Res. 2020; 39(1):246. PMC: 7670601. DOI: 10.1186/s13046-020-01758-w. View

15.

Tang G, Luo L, Zhang J, Zhai D, Huang D, Yin J . lncRNA LINC01057 promotes mesenchymal differentiation by activating NF-κB signaling in glioblastoma. Cancer Lett. 2020; 498:152-164. DOI: 10.1016/j.canlet.2020.10.047. View

16.

Zhang P, Pei X, Li K, Jin L, Wang F, Wu J . Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells. Mol Cancer. 2019; 18(1):179. PMC: 6900862. DOI: 10.1186/s12943-019-1111-2. View

17.

Mu Y, Tang Q, Feng H, Zhu L, Wang Y . lncRNA KTN1‑AS1 promotes glioma cell proliferation and invasion by negatively regulating miR‑505‑3p. Oncol Rep. 2020; 44(6):2645-2655. PMC: 7640367. DOI: 10.3892/or.2020.7821. View

18.

Gong Z, Yu J, Yang S, Lai P, Chen G . FOX transcription factor family in hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer. 2020; 1874(1):188376. DOI: 10.1016/j.bbcan.2020.188376. View

19.

Wei L, Wang X, Lv L, Liu J, Xing H, Song Y . The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol Cancer. 2019; 18(1):147. PMC: 6814027. DOI: 10.1186/s12943-019-1086-z. View

20.

Aleksakhina S, Kashyap A, Imyanitov E . Mechanisms of acquired tumor drug resistance. Biochim Biophys Acta Rev Cancer. 2019; 1872(2):188310. DOI: 10.1016/j.bbcan.2019.188310. View